Additive genetic effects on circulating periostin contribute to the heritability of bone microstructure

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 7, 2015, Pages E1014-E1021

  Bonnet, N ^a   Biver, E ^a   Durosier, C ^a   Chevalley, T ^a   Rizzoli, R ^a   Ferrari, S ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; PROCOLLAGEN; SCLEROSTIN; TELOPEPTIDE; TRANSCRIPTION FACTOR RUNX2; BONE MORPHOGENETIC PROTEIN; CELL ADHESION MOLECULE; GENETIC MARKER; POSTN PROTEIN, HUMAN; SOST PROTEIN, HUMAN;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE STRUCTURE; BONE TURNOVER; CHILD PARENT RELATION; COHORT ANALYSIS; CONTROLLED STUDY; CORTICAL BONE; FEMALE; FEMUR NECK; GENETIC TRAIT; HEREDITY; HERITABILITY; HIP; HUMAN; LUMBAR SPINE; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; POROSITY; PRIORITY JOURNAL; PROGENY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RADIUS; RETROSPECTIVE STUDY; SCLEROSTIN BLOOD LEVEL; SEX DIFFERENCE; TIBIA; TRABECULAR BONE; TRANSCRIPTION FACTOR RUNX2 BLOOD LEVEL; AGED; BLOOD; BONE; EPISTASIS; GENETIC MARKER; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; QUANTITATIVE TRAIT; ULTRASTRUCTURE;

ADULT; AGED; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CELL ADHESION MOLECULES; EPISTASIS, GENETIC; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; PARENT-CHILD RELATIONS; POROSITY; QUANTITATIVE TRAIT, HERITABLE; RETROSPECTIVE STUDIES;

EID: 84944170392     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1183     Document Type: Article

References (47)

1. Ralston SH, Uitterlinden AG. Genetics of osteoporosis. Endocr Rev. 2010;31(5):629-662.
2. Wu S, Liu Y, Zhang L, Han Y, Lin Y, Deng HW. Genome-wide approaches for identifying genetic risk factors for osteoporosis. Genome Med. 2013;29(5):44.
3. Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: Long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18(11):1947-1954.
4. Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone. 2004;34(1):195-202.
5. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; 18(8):1033-1046.
6. Lippuner K, Johansson H, Kanis JA, Rizzoli R. FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int. 2010;21(3):381-389.
7. Johansson H, Kanis JA, McCloskey EV, et al. A FRAX model for the assessment of fracture probability in Belgium. Osteoporos Int. 2011;22(2):453-461.
8. Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005;90(12):6508-6515.
9. Nishiyama KK, Macdonald HM, Hanley DA, Boyd SK. Women with previous fragility fractures can be classified based on bone microarchitecture and finite element analysis measured with HRpQCT. Osteoporos Int. 2013;24(5):1733-1740.
10. Nagy H, Sornay-Rendu E, Boutroy S, Vilayphiou N, Szulc P, Chapurlat R. Impaired trabecular and cortical microarchitecture in daughters of women with osteoporotic fracture: The MODAM study. Osteoporos Int. 2013;24:1881-1889.
11. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study. J Bone Miner Res. 1999;14(9):1614-1621.
12. Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391-420.
13. Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: A cross-sectional study. Lancet. 2010;375(9727):1729-1736.
14. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: The OFELY study. Osteoporos Int. 2013; 24(2):489-494.
15. Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab. 2013;98(9): 3873-3883.
16. Szulc P, Boutroy S, Vilayphiou N, et al. Correlates of bone microarchitectural parameters and serum sclerostin levels in men: The STRAMBO study. J Bone Miner Res. 2013;28(8):1760-1770.
17. Bonnet N, Rousseau JC, Garnero P, Ferrari SF. Periostin: A novel serum marker of cortical bone formation. J Bone Miner Res. 2011: c151.
18. Garnero P. New developments in biological markers of bone metabolism in osteoporosis. Bone. 2014;66:46-55.
19. Rani S, Barbe MF, Barr AE, Litvin J. Periostin-like-factor and Periostin in an animal model of work-related musculoskeletal disorder. Bone. 2009;44(3):502-512.
20. Bonnet N, Standley KN, Bianchi EN, Stadelmann V, et al. The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem. 2009;284(51):35939-35950.
21. Rhee Y, Allen MR, Condon K, et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res. 2011;26(5):1035-1046.
22. Bonnet N, Ferrari S. L. Periostin expression mediates SOST inhibition and cortical bone anabolic response to PTH. Bone. 2010; 47(suppl):s46.
23. Gerbaix M, Vico L, Ferrari SL, Bonnet N. Periostin expression contributes to cortical bone loss during unloading. Bone. 2015;71:94-100.
24. Contié S, Voorzanger-Rousselot N, Litvin J, et al. Development of a New ELISA for Serum periostin: Evaluation of growth-related changes and bisphosphonate treatment in mice. Calcif Tissue Int. 2010;87(4):341-350.
25. Anastasilakis AD, Polyzos SA, Makras P, et al. Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment. Horm Metab Res. 2014;46:145-149.
26. Rousseau J, Sornay-Rendu E, Bertholon C, Chapurlat R, Garnero P. Serum periostin is associated with fracture risk in postmenopausal women: A 7 years prospective analysis of the OFELY study. J Clin Endocrinol Metab. 2014;3893:1-7.
27. Chevalley T, Bonjour JP, van Rietbergen B, Ferrari S, Rizzoli R. Fracture history of healthy premenopausal women is associated with a reduction of cortical microstructural components at the distal radius. Bone. 2013 55(2):377-383.
28. Ferrari S, Rizzoli R, Slosman D, Bonjour JP. Familial resemblance for bone mineral mass is expressed before puberty. J Clin Endocrinol Metab. 1998 83(2):358-361.
29. Krall EA, Dawson-Hughes B. Heritable and life-style determinants of bone mineral density. J Bone Miner Res. 1993;8(1):1-9.
30. Bjørnerem Å, Bui M, Wang X, et al. Genetic and environmental variances of bone microarchitecture and bone remodeling markers: A twin study. J Bone Miner Res. 2015;30(3):516-524.
31. Garnero P, Arden NK, Griffiths G, Delmas PD, Spector TD. Genetic influence on bone turnover in postmenopausal twins. J Clin Endocrinol Metab. 1996;81(1):140-146.
32. Hunter D, De Lange M, Snieder H, et al. Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res. 2001;16(2):371-378.
33. Wagner H, Melhus H, Pedersen NL, Michaëlsson K. Genetic influence on bone phenotypes and body composition: A Swedish twin study. J Bone Miner Metab. 2013;31(6):681-689.
34. Duncan EL, Cardon LR, Sinsheimer JS, Wass JA, Brown MA. Site and genderspecificityofinheritanceofbonemineraldensity. JBoneMinerRes. 2003;18(8):1531-1538.
35. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide metaanalysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012 44(5):491-501.
36. Xiao SM, Gao Y, Cheung CL, et al. Association of CDX1 binding site of periostin gene with bone mineral density and vertebral fracture risk. Osteoporos Int. 2012;23(7):1877-1887.
37. Galea GL, Price JS, Lanyon LE. Estrogen receptors' roles in the control of mechanically adaptive bone (re)modeling. Bonekey Rep. 2013;2:413.
38. Kuipers AL, Zhang Y, Yu S, et al. Relative influence of heritability, environment and genetics on serum sclerostin. Osteoporos Int. 2014;25(3):905-912.
39. Meyer S, van der Meer P, van Deursen VM, et al. Neurohormonal and clinical sex differences in heart failure. Eur Heart J. 2013; 34(32):2538-2547.
40. Parfitt AM. Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem. 1994;55(3):273-286.
41. Wachter NJ, Augat P, Krischak GD, et al. Prediction of strength of cortical bone in vitro by microcomputed tomography. Clin Biomech (Bristol, Avon). 2001;16(3):252-256.
42. Wachter NJ, Krischak GD, Mentzel M, et al. Correlation of bone mineral density with strength and microstructural parameters of cortical bone in vitro. Bone. 2002;31(1):90-95.
43. McCalden RW, McGeough JA, Barker MB, Court-Brown CM. Age-related changes in the tensile properties of cortical bone. The relative importance of changes in porosity, mineralization, and microstructure. J Bone Joint Surg Am. 1993;75(8):1193-1205.
44. Bala Y, Zebaze R, Ghasem-Zadeh A, et al. Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res. 2014;29(6):1356-1362.
45. Bao S, Ouyang G, Bai X, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004;5(4):329-339.
46. Masuoka M, Shiraishi H, Ohta S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122(7):2590-2600.
47. Bible E. Polycystic kidney disease: Periostin is involved in cell proliferation and interstitial fibrosis in polycystic kidney disease. Nat Rev Nephrol. 2014;10(2):66.